ARHGAP21 and myelodysplastic syndrome: ARHGAP21 expression was also increased in MSCs from de novo AML when compared to MDS [0.20 (0.00–1.65)], p = 0.0001, and AML-MRC patients [0.22 (0.43–0.32)], p = 0.0009.